

REMARKS

In response to the Examiner's action dated September 18, 2002, applicant provisionally selects Group II, claims 1-11, 14-23 25 and 26 for examination on the merits in this application


To advance matters, claims 1 has been amended to be limited to the type of effector originally defined in claim 11. For this reason, claim 11 has been cancelled.

An action on the merits of the elected claims is requested.

Attached is a version with markings to show changes made to the claims

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

By 

Jay M. Finkelstein
Registration No. 21,082

JMF:lt

Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
G:\BN\C\cohn\Nathan9\PTO\amendment 1JUL.03.doc

Version with Markings to Show Change Made to the Claims

1. A prodrug for use in inducing a physiological effect in a target cell population comprising a drug which can be converted from an inactive form, in which it does not induce said physiological effect, to an active form in which it induces said physiological effect, the prodrug comprising the drug in its inactive form and being characterized by:

the prodrug comprises a complex between a nucleic acid molecule and said drug in the inactive form; the nucleic acid molecule being capable of transition from a catalytically inactive form to a catalytically active form in which catalytically active form the nucleic acid molecule causes said drug to convert to the physiologically active form; said transition of the nucleic acid molecule is dependent on the presence of an effector being a nucleic acid sequence-an ion, a molecule or a moiety within a molecule.